The Zhitong Finance App learned that on Thursday, Davion Healthcare Plc (DAVI.US) entered the US stock market. After opening, the stock price fell more than 12% to $10.73. The IPO price is $12.25. Davion Healthcare Plc is an Ireland-based medical technology company focused on developing and commercializing non-invasive home health monitoring technology to help consumers detect potential health abnormalities early. The company's flagship product, BreastCheck, is a home breast health screening product registered with the US Food and Drug Administration (FDA). It can identify potential abnormalities by monitoring changes in breast surface temperature. The test process takes less than 15 minutes. The results can be viewed through a mobile app or internet, but it cannot replace mammography or clinical diagnosis.

In addition, the company is also developing products for blood circulation, testicular health, skin abnormalities, and wound monitoring. Davion plans to expand its business scale through commercialization of its own products and the acquisition of complementary medical companies.

According to the company's prospectus, it has not yet generated revenue in 2025 and is still in the early stages of commercialization.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.